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T cell receptor (TCR) genetic diversity is outnumbered by
thequantity of pathogenic epitopes tobe recognized.Toprovide
efficient protective anti-viral immunity, a single TCR ideally
needs to cross-react with a multitude of pathogenic epitopes.
However, the frequency, extent, andmechanisms of TCR cross-
reactivity remainunclear,with conflicting results on anti-viral T
cell cross-reactivity observed in humans. Namely, both the pres-
ence and lack of T cell cross-reactivity have been reported with
HLA-A*02:01-restricted epitopes from the Epstein-Barr and
influenza viruses (BMLF-1 and M158, respectively) or with the
hepatitis C and influenza viruses (NS31073 and NA231, respec-
tively). Given the high sequence similarity of these paired viral
epitopes (56 and 88%, respectively), the ubiquitous nature of the
three viruses, and the high frequency of theHLA-A*02:01 allele,
we selected these epitopes to establish the extent of T cell cross-
reactivity. We combined ex vivo and in vitro functional assays,
single-cell TCR repertoire sequencing, and structural analy-
sis of these four epitopes in complexwithHLA-A*02:01 todeter-
mine whether they could lead to heterologous T cell cross-reac-
tivity. Our data show that sequence similarity does not translate
to structural mimicry of the paired epitopes in complexes with
HLA-A*02:01, resulting in induction of distinct TCR reper-
toires. The differences in epitope architecture might be an
obstacle for TCR recognition, explaining the lack of T cell cross-
reactivity observed. In conclusion, sequence similarity does not
necessarily result in structuralmimicry, anddespite the need for
cross-reactivity, antigen-specific TCR repertoires can remain
highly specific.
T cells recognize peptides (p) bound to the MHC mole-
cule, or human leukocyte antigen (HLA)4 in humans, via their
T cell receptor (TCR). Each TCR comprises two chains, 
and , that are composed of variable (V), joining (J), and con-
stant (C) genes for the -chain and an additional diversity (D)
segment for the -chain. The TCR has three complementarity
determining regions (CDRs), which determine pHLA specific-
ity (1). Although CDR1 and CDR2 are germ line encoded and
found within the V gene segment, the CDR3 spans the junction
between the V(D)J gene segments. During somatic recombina-
tion, TCR gene segments are rearranged, and the additional
insertion/deletion of nucleotides at each gene junction creates a
high level of diversity within the CDR3, termed a hypervariable
loop (2). Thus, theCDR3 loops are often used to define epitope-
specific TCR clonotypes.
The clonal selection theory (3) suggests that protective
immunity is a “one clonotype, one specificity” system, in which
a single TCR recognizes a single pHLA complex. However, this
theory was questioned by Mason (4), who hypothesized that
1015 T cells would be required to recognize 1015 non-self pep-
tides. Because theweight of 1015T cells would bemore than 500
kg in one individual, such single specificity of T cells is mathe-
matically impossible. This suggests that eachT cellmust be able
to recognize a vast number of peptides to ensure protective
immunity in a process known as cross-reactivity. Thus, T cell
cross-reactivity is critical for the efficacy of the immune system,
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wherebyT cells exposed to one epitope can recognize viral vari-
ants (5–7) to provide immune protection upon subsequent
challenge (5).
T cell cross-reactivity can also occur during viral infections,
in which effector or memory CD8 T cells can recognize
epitopes from an unrelated virus, a process known as heterolo-
gousT cell cross-reactivity.HeterologousT cell cross-reactivity
has been extensively characterized in murine models, in which
mice primed with one virus can be subsequently challenged
with an unrelated virus during the effector phase (8–12). Stud-
ies using similar viruses, such as lymphocytic choriomeningitis
virus (LCMV) and Pichinde virus (9), or distinct viruses, such as
LCMV and vaccinia virus (VV) (10), have shed some light onto
the mechanisms of heterologous cross-reactivity. For example,
the H-2Kb-restricted NP205 epitope from both LCMV
(YTVKYPNL) andPichinde virus (YTVKFPNM)are 75% iden-
tical, with differences only at position (P) 5 and P8 (9). Struc-
tures of the twoH-2Kb-NP205 peptides revealed that P5 and P8,
which share similar residues, were both buried inside the anti-
gen-binding cleft, thereby enabling a high level of cross-reac-
tivity toward these distinct viral peptides. Conversely, others
have shown that heterologous cross-reactivity can occur
toward epitopes with lower sequence identity. For example, the
LCMV gp34 epitope (AVYNFATM) and the VV A11R198
epitope (AIVNYANL) share three identical residues (37% iden-
tity). However, previous exposure to LCMV provided a level of
protection against VV (13). Despite sharing only three identical
residues, the two pMHC complexes adopted similar structures,
with the variable amino acids buriedwithin the antigen-binding
cleft, thus providing amolecular basis for T cell cross-reactivity
(14).
A recent study utilizing a library of peptides containing sys-
tematic substitutions showed that TCRs are predominantly
cross-reactive because they are tolerant of peptide residue sub-
stitutions rather than recognizing multiple distinct peptides
(14). Moreover, the “tolerated” substitutions were either not in
direct contact with the TCR or were conservative and thus per-
mitted binding by the TCR, in line with the observations from
Shen et al. (13). This suggests that T cells can cross-recognize
distinct pMHC complexes because they are permissive of sub-
stitutions and recognize specific pMHC architectures rather
than degeneracy inTCRbinding. Accordingly, only a handful of
studies have shown how a single TCR could engage highly
divergent pMHC complexes (15–18).
Although heterologous immunity inmice is well established,
there is controversy regarding heterologous T cell cross-reac-
tivity in humans and its impact on protective anti-viral immu-
nity. For example, studies have described the presence (19, 20)
or absence (21) of heterologous CD8 T cell cross-reactivity
toward the HLA-A*02:01-restricted influenza-derived (M158,
GILGFVFTL) and Epstein-Barr virus (EBV)-derived (BMLF-
1, GLCTLVAML) epitopes. Similarly, other studies have
described the presence (22–24) or absence (25, 26) of heterol-
ogous CD8 T cell cross-reactivity toward the HLA-A*02:01-
restricted influenza-derived (NA231, CVNGSCFTV) and hepa-
titis C virus (HCV)-derived (NS31073,CINGVCWTV) epitopes.
Interestingly, both NS31073 and NA231 epitopes exhibit varia-
tions between distinct viral strains, whichmay explain the vari-
able frequency of cross-reactivity between individuals (22, 26),
because a single amino acid substitution can impact the CD8
T cell frequency and cross-reactivity (27).
Based on the previous reports of human heterologous cross-
reactivity (20, 23, 24, 28), we focused our current study on the
well described and highly prevalent HLA-A*02:01-restricted
epitopes, namely M158/BMLF-1 and NS31073/NA231. These
paired peptides share identical (3 and 6, respectively) as well as
chemically conserved (2 each) residues, with a sequence homo-
logy of 56 and 88%, respectively. Therefore, they provide a good
model to determine the molecular basis underlying heterolo-
gous T cell cross-reactivity in humans.
In this study, we combined single-cell TCR repertoire
sequencing with biophysical and structural analysis of the four
epitopes in complex with the HLA-A*02:01 molecule. We also
undertook functional studies (including ex vivo and in vivo T
cell expansion in healthy individuals for both peptide pairs and
in HCV-infected individuals for the NS31073/NA231 peptide
pair) to determine the frequency and biological relevance of
heterologous T cell cross-reactivity toward these HLA-A*02:
01-restricted epitopes. Our data show that the sequence simi-
larity between the paired epitopes did not translate to structural
mimicry. Namely, the paired epitopes exhibited distinct archi-
tectures andmobility within theHLAbinding cleft and selected
distinctTCR repertoires. Together, these findings underlie a
lack of heterologous cross-reactivity detected directly ex vivo by
tetramer enrichment and in vitro via IFN- and tetramer
assays. Whereas T cell cross-reactivity is an intrinsic require-
ment for protective immunity, our data indicate that the
sequence similarity of peptides alone is not a reliable indication
of CD8 T cell cross-reactivity. In line with previous studies
(13, 14), our results highlight that pHLA architecture impacts
CD8 T cell cross-reactivity.
Results
Lack of Structural Homology between Paired Epitopes—To
understand the mechanisms underpinning human heterolo-
gous CD8 T cell cross-reactivity, we selected two pairs of
prominent human epitopes containing viral peptides derived
from three ubiquitous viruses (influenza, HCV, and EBV) that
display high sequence similarity and are restricted by HLA-
A*02:01. Conflicting literature reports either the presence (20,
23, 24) or lack (21, 25, 26) of heterologous CD8 T cell cross-
reactivity between HLA-A*02:01-restricted epitopes M158
(GILGFVFTL) and BMLF-1 (GLCTLVAML) epitopes, as well
as NA231 (CVNGSCFTV) and NS31073 (CINGVCWTV).
The M158 and BMLF-1 epitopes share 56% sequence homo-
logy, with three identical residues at P1-Gly, P6-Val, and
P9-Leu (similarly to the LCMVgp34 andVVA11R198 epitopes),
as well as chemically conserved P2-I/L and P5-F/L residues.
The NA231 and NS31073 peptides share higher sequence homo-
logy (88%). To determine whether the sequence variation could
impact the stability of each peptide within the HLA-A*02:01
antigen binding cleft, we performed a thermal stability assay.
The thermalmelting point (Tm) values were very similar for the
paired pHLA complexes, with a Tm of 59 °C for M158 and
BMLF-1 and of56 °C for NA231 and NS31073, suggesting that
each pHLA complex displays similar stability.
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We next compared the four peptide-HLA-A*02:01 struc-
tures (Fig. 1). The structures of HLA-A*02:01 in complex
with NS31073 (PDB code 3MRG (27)), BMLF-1 (PDB code
3MRE (27)), and M158 (PDB code 2VLL (29)) were deter-
mined previously, and here we report the HLA-A*02:01-
NA231 structure to a resolution of 2.0 Å (Table 1). The four
pHLA complexes adopted similar overall structures, with an
average root mean standard deviation of 0.40 Å on the C
atoms of the 12 domains. All four peptides adopted
an extended conformation within the HLA-A*02:01 cleft,
whereby the P2 and P9 residues were used as anchors and
were buried inside the cleft, whereas P3 acted as a partial
anchor residue.
Structure of M158 versus BMLF-1 in Complex with HLA-
A*02:01—The M158 peptide has been referred to as a “plain
vanilla” peptide, because its structure is featureless in the cleft
of HLA-A*02:01; the two large Phe residues at P5 and P7 are
buried inside the cleft, and only the small P6-Val side chain is
exposed for TCR contact (Fig. 1a, panel i) (29–31). The P5-Leu
and P7-Ala of the BMLF-1 peptide (27) adopted a buried con-
formation similar to the P5 and P7 of theM158 epitope (Fig. 1a,
panel ii); however, the smaller P5 and P7 side chains of the
BMLF-1 peptide were shifted toward the HLA 2-helix. As a
result, the conserved P6-Val adopted a more central and fully
solvent-exposed conformation in the BMLF-1 peptide than in
the M158 peptide (C displacement of 1.6 Å; Fig. 1a, panel iii).
FIGURE1.Structural differencesbetweenpeptidepairs bound to theHLA-A*02:01molecule. Thepanels represent theHLA-A*02:01 cleft inwhite cartoon,
bound to the four different peptides in stick format. a, structures of theM158 peptide in cyan (panel i), BMLF-1 in orange (panel ii), and a superposition of the two
peptides in complexwithHLA-A*02:01 (panel iii).b, histogramof the relativemeanB factors for theM158 (cyan) andBMLF-1 (orange) peptides. For eachpeptide
residue, 100 ((BresidueBHLA-A*02:01-12)/BHLA-A*02:01-12) was calculated, with positive values representing a peptide residuemoremobile than
the overall HLA 12 domains, and negative values representing a peptide residue more stable. c, structures of the NA231 peptide in brown (panel i), NS31073
in green (panel ii), and a superposition of the two peptides in complex with HLA-A*02:01 (panel iii). d, histogram of the relative mean B factors for the NA231
(brown) and NS31073 (green) peptides, calculated as per B.
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Moreover, as judged by temperature factor analyses (relative B
factor of each peptide residue compared with the HLA antigen
binding cleft B factor), the central part (P4–P7) of the BMLF-1
peptide was more flexible than the M158 peptide, with a maxi-
mummobility at the conserved P6-Val (Fig. 1b). Peptidemobil-
ity can influence peptide conformation, as well as CD8 T cell
recognition (32, 33). Therefore, despite a conserved P6-Val and
56% sequence homology, the M158 and BMLF-1 peptides were
presented differently by the HLA-A*02:01 molecule.
Structure of NA231 versus NS31073 in Complex with HLA-
A*02:01—Despite the sequence similarity of the NA231 and
NS31073 epitopes (27), the structures of both peptides differed
(Fig. 1c). For example, the conserved aromatic residue at P7
(NS31073 P7-Trp; NA231 P7-Phe) adopted contrasting confor-
mations. The NA231 P7-Phe was buried inside the cleft and
interacted with Trp147 and His114 of HLA-A*02:01 (Fig. 1c,
panel i) and was not available for TCR recognition. Conversely,
theNS31073 P7-Trpwas solvent-exposed, with its aromatic side
chain potentially available for TCR interaction (Fig. 1c, panel
ii). The different P7 conformations changed the central part
of the peptide (Fig. 1c, panel iii), resulting in the conserved
P6-Cys sitting higher in the HLA-A*02:01 cleft for the NA231
peptide compared with NS31073 (C deviation of 2.4 Å). This
resulted in a 20% decrease in TCR accessible surface area for
the NA231 peptide (270 Å2) compared with NS31073 (335 Å2)
(Fig. 1c, panel iii). Temperature factor analysis revealed that
the NS31073 peptide was rigid, whereas the NA231 peptide
showed higher mobility at P4 to P6 (Fig. 1d). Taken together,
the structural analysis revealed that HLA-A*02:01 presents
the two peptide pairs with distinct epitope conformations
and differing flexibility.
CD8 T Cells Utilize Distinct TCR Repertoires to Recog-
nize the Epitopes Pairs—Next, we asked whether the respond-
ing TCR repertoires showed any overlap in response to the
paired HLA-A*02:01-restricted M158/BMLF-1 and NS31073/
NA231 epitopes.We investigated theTCR clonotypes (Fig. 2)
and CDR3 usage (Fig. 3) in M158- and BMLF-1-reactive
CD8 T cell lines (Fig. 2a) or in NA231CD8 and
NS31073CD8 T cells generated directly ex vivo from healthy
donors following tetramer magnetic enrichment (Fig. 2b). In
addition,we assessed the recognition ofNS31073 byCD8Tcell
lines from donors with chronic HCV infection (Fig. 2c).
CD8tetramer cells were single cell-sorted, and the TCR
repertoire was determined using human RT-PCR multiplex
(34).
TheM158-specificTCR repertoirewas quite diverse in the
three donors (12–19 clonotypes/donor from27–32 sequences).
The M158-specific TCR clonotypes were highly biased
toward TRBV19 gene usage (96.3 3.7%) and paired with dif-
ferent TRAV chains (Table 2 and Fig. 2a, panel i), in line with
previously published repertoires (35, 36). Distinct M158 clono-
types favored a CDR3 length of 9 amino acids (aa) (29.9 
17.4%) (Fig. 3a, panel i) and a short CDR3 of 8 aa (74.6 0.8%)
(Fig. 3a, panel ii). Multiple CDR3 sequences were observed
(GGSQGNL, GGTSYGKL, and SSNTGKL) (Table 2) sharing
the Z3–4XGmotif (Fig. 3b, panel i), where Z represents a small
amino acid (Gly, Ser, or Thr), and X represents any residue,
irrespective of the TRAV gene pairing. This motif is known to
allow the CDR3 loop to closely contact P4-P5 of the peptide
(31). The commonCDR3 RSmotif was detected in 28, 63, and
74% of total sequences from donors H-1, H-2, and H-3, respec-
tively (Table 2 and Fig. 3b, panel i), consistent with previously
published data (30, 35, 36).
The BMLF-1-specific TCR repertoire was relatively more
restricted (5–7 clonotypes/donor from 27–32 sequences)
(Table 2; Fig. 2a, panel ii). A bias for the TRAV5/TRBV20 pair-
ing was observed in all donors (100, 9.7, and 40.7% in H-1, H-2,
and H-3 donors, respectively) (Table 2), consistent with previ-
ously published data (37). Furthermore, the same CDR3 loop
sequence (DNNARL) was observed in the H-1 donor (84%) and
the H-3 donor (4%), with conserved sequences found in donor
H-2 (D(S/Q)NARL, 9%) (Table 2). The distinct CD8 T cell
clonotypes from the three donors preferred a short CDR3 of 6
aa (48.4 45.1%) (Fig. 3a, panel i) with a conserved DXNARL
motif (Fig. 3b, panel ii) and a preferred an 8-aa-long CDR3
(63.5  33.8%) (Fig. 3a, panel ii) exhibiting shared motif
(RXXXGN, Fig. 3b, panel ii).
There were no evident TRAV or TRBV biases in the NA231-
specific CD8 T cells (Table 3 and Fig. 2b, panel i). The most
common CDR3 lengths for the distinct clonotypes were 8 or
10 aa (both 28.3 10.4%) (Fig. 3a, panel i), whereas CDR3was
most commonly 10 aa long (26.7 30.6%) (Fig. 3a, panel ii). No
shared motifs were observed within either of the CDR3 loops
(Fig. 3b, panel iii). The number of NA231-specific TCRs avail-
able was low because of their low pHLA affinity and the pre-
dominant naïve phenotype of the NA231-specific CD8T cells.
The NS31073 TCR repertoire was characterized by a lim-
ited TCR diversity in donors with chronic HCV infection.
HCV-1 had sevenNS31073-specific clonotypes, whereasHCV-2
had a more limited repertoire with only four clonotypes (Fig.
2c). A TRAV4 bias was observed in the TCR repertoire of both
healthy (37.8  20.4%) and HCV-infected donors (59.1 
TABLE 1
Data collection and refinement statistics
HLA-A*02:01-NA231
Data collection statistics
Temperature (K) 100
Space group P21
Cell dimensions
a, b, c (Å) 51.45, 80.06, 55.00
 (°) 111.36
Resolution (Å) 100–2.00 (2.10–2.00)
Total number of observations 87,946 (11,254)
Number of unique observations 26,350 (3398)
Multiplicity 3.3 (3.3)
Data completeness (%) 93.5 (89.4)
I/I 11.18 (3.57)
Rmerge (%)a 10.0 (39.0)
Refinement statistics
Non-hydrogen atoms
Protein 3259
Water 372
Rfactor (%)b 19.4
Rfree (%)b 25.8
Root mean square deviations from ideality
Bond lengths (Å) 0.008
Bond angles (°) 1.165
Ramachandran plot (%)
Favored 98.48
Outliers 0
a Rmerge	 
IhklIhkl/
Ihkl.
b Rfactor	 
hklFo Fc/
hklFo for all data except5%, which were used for
Rfree calculation. The values in parentheses are for the highest resolution shell.
Heterologous CD8 T Cell Cross-reactivity in Humans
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15.4%), which paired with a range of TRBVs (Fig. 2, b and c),
despite the low number of NS31073-specific CD8 T cells iso-
lated from healthy donors because of their predominant naïve
phenotype. In addition, the HCV-1 donor showed a preference
for TRAV5 (38%) (Fig. 2c). The NS31073-reactive repertoire
from both healthy and HCV-infected individuals consisted of
distinct clonotypes with different CDR3 lengths, with the most
common CDR3 length of 10 aa (26.4 18.4%) (Fig. 3a, panel
i) and the most common CDR3 length of 9 aa (26.3 24.5%)
(Fig. 3a, panel ii).
Overall, no commonTCR clonotypes were utilized for the
recognition of M158 and BMLF-1 or the NA231 and NS31073
peptides. On a broader level, only a single common TRAV8/
TRBV28 pair was identified in the NA231 and NS31073 TCR
repertoires; however, they were completely distinct clonotypes.
Furthermore, no common TRAV/TRBV pairs were detected in
FIGURE 2. Distinct TCR repertoires recognize each peptide in complex HLA-A*02:01. PBMCs from healthy and HCV-infected donors were stimulated
with theM158 or BMLF-1peptides (13days) or theNS31073 peptide (19–21days). CD8
T cell lineswere stainedwith the cognatepeptide,whereas PBMCs (from
healthy donors) were stained with either NA231QE or NS31073 tetramers and were magnetically enriched. The cells were stained as lymphocytes, singlets,
CD3mid-high, dump (PBMCs only), CD8, tetramer cells, and single-cell sorted. Then the TCR repertories were determined using a multiplex RT-PCR. a,
TCR repertoire utilized to recognize the M158 (panel i) or BMLF-1 (panel ii) tetramers (in H-1, H-2, and H-3 healthy donors). b, TCR repertoire utilized to
recognize NA231QE (panel i) or NS31073 (panel ii) tetramers (in H-4, H-5, H-6, and H-7 healthy donors). c, NS31073 tetramer
 TCR repertoire (HCV1 and HCV-2
are HCV-infected donors).
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the M158 and BMLF-1 TCR repertoires. These findings fur-
ther highlight the high level specificity ofmemory CD8T cells
for their pHLA. Thus, despite high sequence homology, the
paired peptides were structurally different and mobilized dis-
tinct TCR repertoires with no overlap.
Lack of T Cell Cross-reactivity Observed for the Paired HLA-
A*02:01-restricted Epitopes as Assessed Directly ex Vivo—Based
on our findings on differing TCR repertoires, we next inves-
tigated heterologous cross-reactivity directly ex vivo from
human peripheral bloodmononuclear cells (PBMCs).We used
a magnetic enrichment technique (38, 39) for an unbiased
detection of low-frequency epitope-specific CD8 T cells.
PBMCs from healthy HLA-A*02:01-positive donors were
stained with the specific HLA-A*02:01 tetramer, positively
enriched, and surface-stained using CD3, CD8, dump
(CD4, CD14, and CD19), and phenotypic antibodies (Fig.
4a). Using the phenotypic antibodies CD27 and CD45RA,
M158- and NS31073-specific CD8 T cells from healthy donors
were analyzed for their activation phenotype, respectively (Fig.
4b). Furthermore, using the CD8 enhanced (40) HLA-A*02:
01-Q115E-NA231 mutant tetramer (NA231QE), we detected
low affinity NA231-specific CD8T cells, which were undetect-
able with the WT tetramer (Fig. 4c). We identified memory
M158- and BMLF-1-specific CD8 T cells across donors with a
mean frequency of 5  105 and 1  104, respectively (Fig.
4d). Low affinity NA231- and naïve CD27CD45RA NS31073-
specific CD8 T cells were found at lower frequencies compa-
rable with other studies (39), at 3 106 and 4 106, respec-
tively (Fig. 4d).
To identify any cross-reactive CD8 T cells directly ex vivo,
PBMCs from healthy and HCV donors (Table 4) were co-
stainedwith eitherM158 and BMLF-1 orNA231QE andNS31073
tetramers conjugated to different fluorochromes, followed by
tetramer magnetic enrichment (Fig. 5). Memory M158- and
BMLF-1-specificCD8Tcell populationswere detected at an
average of 12.0 7.8 and 20.4 16.1% of CD8T cells, respec-
tively (Fig. 5b,panel i). Similarly, naïveNS31073- and low affinity
NA231-specific CD8 T cells were detected in healthy donors
FIGURE 3. Epitope-specific CDR3motifs are conserved between donors. a, CDR3 (panel i) and CDR3 (panel ii) length used by distinct antigen-specific
CD8 T cell clonotypes for recognition of M158 (cyan), BMLF-1 (orange), NA231 (brown), and NS31073 (green) peptides. The colored bar represents the most
frequent CDR3 length for each peptide. b, analysis of the CDR3 motifs (of the most common lengths) used by distinct clonotypes in the recognition of M158
(panel i), BMLF-1 (panel ii), NA231 (panel iii), and NS31073 (panel iv). n	 number of distinct clonotypes.
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TABLE 2
TCR repertoire usage for the recognition of M158 and BMLF-1
Code represents the individual clonotypes. The colored residues represent the conservedmotifs within the CDR3 loops between donors, in which blue is the Z3–4XGmotif
(Z is a small amino acid, and X is any residue), red is the RS motif of the M158-specific clones, purple is the DXNARL motif, and green is the RXXXGN motif of the
BMLF-1-specific clones. Each clonotype frequency is expressed as the proportion of total sequences. TRAV, variable -chain gene usage; TRBV, -chain gene usage; TRAJ,
junction -chain gene usage; TRBJ, junction -chain gene usage; H, individual donor.
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with mean frequencies of 2.2 1.4 and 2.2 1.2% of CD8 T
cells, respectively (Fig. 5b, panel ii). Memory NS31073-specific
CD8T cell populations were detected at a higher frequency in
donors with chronic HCV infection (13.0  3.0%, Fig. 5, c and
d). No discernable cross-reactive population was observed for
either set of epitopes, of which only 0.19 0.16 or 0.09 0.08%
of CD8 T cells in healthy donors were M158BMLF-1 or
NA231NS31073, respectively. Similarly, only 0.10 0.14% of
CD8 T cells were NA231NS31073 in HCV-infected donors
(Fig. 5d).
Lack of Heterologous Cross-reactivity after in Vitro Ampli-
fication—To determine whether the reported heterologous
cross-reactivity could be a consequence of an in vitro amplifi-
cation, epitope-specific CD8 T cell lines from healthy (Fig. 6)
or HCV-infected donors (Fig. 7 and Table 4) were assessed for
cross-reactivity by tetramer co-staining and an IFN intracel-
lular cytokine staining (ICS) assay.M158 and BMLF-1CD8
T cell lines specifically responded to their cognate peptide, with
22.4 16.8 and 17.9 7.1% of the tetramerCD8Tcells (Fig.
6, a and b) and 25.0 12.3 and 9.7 7.5% being IFNTNF,
respectively (Fig. 6, c andd). The frequency ofCD8Tcells able
to bind both tetramers and produce IFNTNF was just
above background, showing the absence of CD8T cells able to
cross-react on both the M158 and BMLF-1 epitopes (Fig. 6).
Unlike previous studies (24), CD8 T cells did not expand in
the presence of NA231, and only 0.06 0.04% and 0.19 0.17%
of CD8 T cells were NA231-tetramer or IFNTNF in an
ICS assay, respectively (Fig. 7, a and c). Conversely, NS31073-
specific CD8Tcells could be detected at 14.3 11.7 and 4.0
3.5% in the tetramer and ICS assays, respectively (Fig. 7, b and
d). No cross-reactivity was detected in NA231 or NS31073-stim-
ulated CD8 T cell lines either by tetramer co-staining (0.02
0.01 and 0.09  0.14% of CD8 T cells) (Fig. 7, a and b) or in
the ICS assay (0.15  0.11 and 0.60  0.99% of CD8 T cells
were IFNTNF), respectively (Fig. 7, c and d). Together,
these ex vivo and in vitro data highlight the lack of heterolo-
gous cross-reactivity toward M158 and BMLF-1 or NA231
and NS31073 epitopes, even following extended in vitro
amplification.
No Cross-reactivity between Different NA231 Variant Pep-
tides—Based on the low number of NA231 tetramer CD8 T
cells detected in our study, and because theNAprotein is highly
variable, we investigated whether the donors may have been
exposed to other NA variants.We first examined the conserva-
tion of the NA231 peptide in the pH1N1, recent trivalent sea-
sonal influenza vaccine strains, andOceania-originated isolates
(Table 5). A total of 28 variant peptides were identified. Muta-
tions were common in the anchor P2 and P9 residues (buried
residues; Fig. 1c), which are unlikely to affect TCR binding
(Table 5). The P2 mutation, V2I, was common to the vaccine
(71%) and Oceania (67%) isolates and thus further increased
the sequence homology to the NS31073 peptide. Three major
variants from the NA231 WT CVNGSCFTV were identified
and chosen for further analysis, namely CINGTCTVV (P2-
Ile-P5-Thro-P7-Thr-P8-Val), CVNGSCFTI (P9-Ile), and CI
NGSCFTI (P2-Ile-P9-Ile) (Table 5).
To assess whether our HCV-infected donors had been
exposed to a different NA231 variant (Table 5), CD8 T cell
lines were established against each or a pool of the peptides
containingWTNA231 and three NA231 variants, as well as WT
NS31073 and a single NS31073 variant. No NA231-specific CD8
T cells were expanded, despite extended in vitro amplification
of up to 18 days (Fig. 8a). CD8 T cells were successfully
expanded against theNS31073 peptides in both donors (Fig. 8b),
TABLE 2—continued
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andCD8Tcells stimulatedwith the pool of peptideswere able
to respond only to both NS31073 peptides (Fig. 8c). Together,
these data show that there is no cross-reactivity between WT
and variants NA231 with NS31073 in donors with chronic HCV
infection, in line with previously published data (26).
Discussion
Heterologous T cell cross-reactivity is a phenomenon
whereby an individual CD8 T cell can recognize and respond
tomore than one viral antigen derived from unrelated viruses
(41). It has the potential to be either beneficial, by increasing
the chances that any given viral peptide is recognized by a
CD8 T cell (28), or detrimental, by contributing to the
CD8 T cell-mediated immunopathology associated with
diseases such as EBV and HCV infection (23, 24). Because
the few reports on T cell cross-reactivity in humans have
shown conflicting results (20–25, 41), we investigated four
epitopes from ubiquitous viruses (influenza, EBV, and HCV)
restricted by the highly prevalent HLA-A*02:01 molecule.
We aimed to elucidate the extent (if any) of the proposed
heterologous cross-reactivity toward two distinct sets of
HLA-A*02:01 restricted peptides: M158 (29) with BMLF-1
(27) and NA231 with NS31073 (27).
The most likely mechanism for heterologous T cell cross-
reactivity would be that an individual CD8 T cell with a
single TCR can recognize unrelated but similar pHLA com-
plexes. This suggests that molecular mimicry would under-
pin heterologous T cell cross-reactivity, in a similar fashion
to the interepitope cross-reactivity (5). Structures of theHLA-
A*02:01 in complex with each paired peptide showed, however,
that despite the sequence similarity of the paired peptides, the
pHLA complexes display distinct architectures.
TABLE 3
TCR usage for the recognition of NA231 and NS31073
Code represents the individual clonotypes. TRAV, variable-chain gene usage; TRBV,-chain gene usage; TRAJ, junction-chain gene usage; TRBJ, junction-chain gene
usage; H, individual donor.
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The M158 and BMLF-1 peptides share 56% sequence homo-
logy, and the conserved P6-Val adopts a different conformation
between the two peptides. In BMLF-1, the P6-Val is solvent-
exposed and available for TCR contact, whereas it is buried
within the HLA-binding cleft in the M158 structure (29). This
solvent-exposed P6-Val is important in the recognition of the
BMLF-1 pHLA complex, as demonstrated by the structure of a
prototypical public TCR (AS01) in complex with HLA-A*02:
01-BMLF-1 (37). The highly conserved CDR3 loop positions
itself atop the P6-Val, and the RXXXGNmotif directly interacts
with the P6-Val (36). The BMLF-1 peptide does not undergo
structural change upon AS01 TCR binding, and moreover, ala-
nine substitution of the P6-Val dramatically decreased the TCR
affinity by 13-fold (37). Therefore, the buried conformation of
P6-Val in the M158 complex would prevent binding by BMLF-
1-specific CD8T cells. From the structure of a conserved pro-
totypical TRBV19 TCR (JM22) in complex with HLA-A*02:
01-M158, it was observed that the M158 also does not undergo
structural change upon TCR binding. Therefore, the solvent-
exposed P6-Val of the BMLF-1 pHLA complex would cause
steric clashes with the JM22 CDR3 loop, thus preventing
binding (29, 30).
FIGURE 4. Enumerationof naïve andmemoryHLA-A*02:01-restrictedCD8T cell populations. PBMCs fromhealthyHLA-A*02:01donorswere tetramer-
stained or co-stained with either M158 and BMLF-1 or NA231 and NS31073 conjugated to PE or APC. The samples were magnetically enriched and antibody-
stained (as outlined under “Experimental Procedures”) and gated on lymphocytes, singlets, CD3, dumpCD8, and tetramer. a, representative dot plots
describing the gating strategy used for data analysis of tetramermagnetic enrichment experiments. b, representative dot plots of naïve andmemory tetramer
positive populations and their respective phenotypes usingCD27 andCD45 RA phenotypicmarkers. c, representative dot plots of PBMCs from two donors
stainedwith eitherWTorHLA-A*02:01-QEmutantNA231-specific tetramers and their phenotype usingCCR7 andCD45RAphenotypicmarkers. d, frequency
of naïve, low affinity, and memory epitope-specific CD8 T cell populations in healthy HLA-A*0201 donors after magnetic enrichment.
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With regards to the NA231 and NS31073 peptide pair,
although they have higher sequence homology (88%), they
show opposing conformations for their conserved P6-Cys and
P7-Phe/Trp residues. The NA231 P6-Cys is accessible for TCR
binding, whereas the P7-Phe is buried. Conversely, the NS31073
P6-Cys is buried, and the P7-Trp is solvent-exposed. These
changes completely alter the peptide conformation presented
by HLA-A*02:01 to CD8 T cells for recognition.
Given the structural differences in the pHLA landscapes, the
TCR repertoire being utilized for the recognition of these
peptides was also distinct. Paired analysis from three donors
showed that no common TRAV/TRBV clonotype pairs were
utilized to recognize eitherM158 or BMLF-1. TheM158TCR
repertoire has a distinct TRBV19 bias, as previously reported
(20, 30, 31), whereas the BMLF-1 TCR repertoire has a
TRAV5 bias, which tends to pair with TRBV20–1 (37). Fur-
thermore, the TCR repertoire for recognition of NA231 and
NS31073 was completely unrelated. Together, these data
FIGURE5.LackofheterologousTcell cross-reactivitybetween influenza-M158andEBV-BMLF-1or influenza-NA231andHCV-NS31073detecteddirectly
exvivo.PBMCs fromhealthy andHCV-positiveHLA-A*02:01donorswere tetramer co-stainedwitheitherM158 andBMLF-1orNS31073 andNA231QE tetramers.
Followingmagnetic enrichment, PBMCswere surface-stained (as described under “Experimental Procedures”) and gated on lymphocytes, singlets, CD3, and
dumpCD8.a andb, representative dot plots (a) and summary (b) of (panel i)memoryM158
 andBMLF-1or (panel ii) lowaffinityNA231
 andnaïveNS31073

tetramer CD8 T cells derived from healthy donors (n	 5). The bar charts represent the means with the error bars representing standard deviation. c and d,
representative dot plot (c) and summary (d) of low affinity NA231
 and memory NS31073
-specific tetramer CD8 T cells found in donors with chronic HCV
infection (n	 2). The bar charts represent the means with the error bars representing standard deviation.
TABLE 4
Donors used in this study
H, healthy donor; HCV, HCV-infected donor.
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highlight that the paired peptides are presented differently by
HLA-A*02:01 and consequently elicit very different TCR
repertoires. Thus, it is unlikely that heterologous T cell cross-
reactivity could be occurring at a high frequency in HLA-A*02:
01-positive donors between those two peptide pairs.
Using a combination of ex vivo and in vitro techniques,
including high sensitivity tetramer magnetic enrichment, we
were unable to detect any heterologous memory CD8 T cell
cross-reactivity in healthy (n 	 12) or HCV-infected (n 	 5)
donors. The prominentM158 and BMLF-1 CD8T cell subsets
were identified in all donors directly ex vivo and expanded to
high levels following in vitro amplification. Despite this, no het-
erologous T cell cross-reactivity was detected even following
extensive in vitro amplification. In addition, because the NA
protein is variable between influenza strains, we tested a panel
of common NA231 variants in HCV-infected donors for heter-
ologous T cell cross-reactivity with the NS31073 peptide. How-
ever, no responses were detected against the WT and variant
NA231 peptides. Together, these data imply that heterologousT
cell cross-reactivity is not occurring frequently toward these
epitopes in both healthy and HCV-infected donors.
The precise reasons for the conflicting reports on human
heterologous T cell cross-reactivity are unknown. However,
differences in methodology of T cell culture, donor cohorts,
directionality, and strain specificity of the viral infection might
influence the results. In our study, we have chosen to avoid
prolonged stimulation of CD8 T cells or exposure to high
concentration of numerous cytokines, to reproduce as closely
FIGURE 6. Lack of heterologous T cell cross-reactivitywas observed following in vitro culture of PBMCswith either theM158 or BMLF-1 peptides.M158
and BMLF-1-specific CD8 T cell lines (stimulated for 9–19 days) from healthy donors were assessed for heterologous cross-reactivity by tetramer co-staining
(with PE andAPC) and an IFNTNF ICS assay. All CD8 T cell lineswere antibody-stained (as described under “Experimental Procedures”), and the samples
were gated on lymphocytes, singlets, CD3mid-high, and CD8 T cells. a, representative dot plot (donor H-13) (panel i) and summary (panel ii) of epitope-specific
tetramer CD8 T cells in M158-specific CD8
 T cell lines (n	 3). b, representative dot plot (donor H-13) (panel i) and summary (panel ii) of epitope-specific
tetramer CD8 T cells found in BMLF-1280-specific CD8
 T cell lines (n 	 3). c, representative dot plots (donor H-13) (panel i) and summary (panel ii) of
IFNTNF production (no-peptide control subtracted) derived fromM158-specific CD8
 T cell lines (APCs; n	 6) in response to each peptide and controls.
d, representative dot plots (donor H-13) (panel i) and summary (panel ii) of IFNTNF production (no-peptide control subtracted)made by BMLF-1-specific
CD8T cell lines (APCs;n	6) in response to eachpeptide andcontrols. Thebar charts represent themeanswith the error bars representing standarddeviation.
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as possible a physiological CD8 T cell response. If heterolo-
gous T cell cross-reactivity occurs only in extreme circum-
stances of prolonged and potent T cell stimulation in vitro, it is
therefore unlikely to happen frequently in vivo in humans. As
shown in the present study,NS31073-specific CD8Tcells were
frequent in HCV donors but rare in healthy donors and with
a naïve phenotype, and no cross-reactivity with NA231 was
observed. Conversely, Urbani et al. (22) were able to detect T
cell cross-reactivity for the NA231/NS31073 pair, but only in a
few HCV donors with severe liver pathology. The direction-
ality of viral infection, viral strains, and acute infection could
thus impact on the presence or absence of heterologous CD8
T cell cross-reactivity.
Our data fit within the current published literature (22, 25,
26) and the lack of heterologous CD8 T cell cross-reactivity
observed between the HLA-A*02:01-restricted epitopes (M158
with BMLF-1 and NA231 with NS31073) highlights that
sequence similarity does not translate to structural mimicry
and therefore does not lead to T cell cross-reactivity. In addi-
tion, limited sequence homology can lead to molecular mim-
icry, whereby different pMHC complexes can share structural
features that will in turn be recognized by cross-reactive T cells
(17, 42). Our data also fit with a recent study showing that TCRs
are cross-reactive because of their “tolerance” to peptide
changes (substitution with a similar residue or at a position not
involved with TCR contact), leading to an overall molecular
conservation (14). In conclusion, CD8 T cells can display a
high level of specificity for their pHLA complex because of their
TCR, ensuring that autoimmunity is still a rare event within
the population.
FIGURE 7. Lack of heterologous T cell cross-reactivity following in vitro culture of PBMCs from donors with chronic HCV infection stimulated with either
NS31073orNA231peptides.PBMCsfromHCV-infected individualswerestimulated(for11–27days)withNA231orNS31073peptides,andheterologouscross-reactivity
was evaluated by tetramer co-staining and an IFNTNF ICS assay. The samples were stained (as described under “Experimental Procedures”) and gated on
lymphocytes, singlets,CD3mid-high,andCD8Tcells.a, representativedotplot (donorHCV-2) (panel i)andsummary(panel ii)ofepitope-specific tetramerCD8Tcells
found inNA231-stimulatedCD8
Tcell lines (n	3).b, representativedotplot (donorHCV-2) (panel i) andsummary (panel ii) of epitope-specific tetramerCD8Tcells
found in NS31073-specific CD8
 T cell lines (n	 3). c, representative dot plots (donor HCV-2) (panel i) and summary (panel ii) of IFNTNF production (no-peptide
control subtracted)madebyNA231-stimulatedCD8
Tcell lines (APCs;n	3) inresponsetoeachpeptideandcontrols.d, representativedotplots (donorHCV-2) (panel
i) and summary (panel ii) of IFNTNFproduction (no-peptide control subtracted)derived fromNS31073-specificCD8
Tcell lines (APCs;n	3) in response toeach
peptide and controls. The bar charts represent themeanswith the error bars representing standard deviation.
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Experimental Procedures
Protein Purification, Crystallization, and Structure Deter-
mination—Soluble HLA-A*02:01 containing the M158,
BMLF-1, NA231, or NS31073 peptides were prepared as
described previously (43, 44). Crystals of the HLA-A*02:01 in
complex with the NA231 peptide were grown by the hanging
drop, vapor diffusion method at 20 °C with a protein/reservoir
drop ratio of 1:1, at a concentration of 10 mg/ml in 10 mM
Tris-HCl, pH 8, 150 mM NaCl using 20% PEG 6K, 0.2 M NaCl,
0.1 M sodium citrate, pH 6.5. Prior to being flash frozen in liquid
nitrogen, the crystals were soaked in a cryoprotectant solution
containing mother liquor solution with 30% (w/v) PEG. The
data were collected at the Australian Synchrotron (Clayton,
Australia) on the 3BM1 Beamline (ADSC-Quantum 210 CCD
detector) (45), processed with XDS software (46), and scaled
using XSCALE software (46). The molecular replacement was
performed with the PHASER program (47) using a previously
solved HLA-A*02:01 peptide structure as the search model
(PDB code 3GSO (43)). Manual model building was conducted
using the Coot software (48) followed by maximum-likelihood
refinement with the PHENIX program (49). The final HLA-
A*02:01-NA231 model has been validated using the Protein
Data Base validation web site (Table 1), and the coordinates
have been submitted under the PDB code 5SWQ.Allmolecular
graphics representations were created using PyMOL (50). Pep-
tide sequence alignment was performed using the Clustalw
server, and the sequence homology encompasses identical and
chemically similar residues.
Thermal Stability Assay—To assess the stability of each pep-
tide within the HLA-A*02:01 molecule, a thermal shift assay
was performed as previously described (30).
Human Samples—Buffy packs from healthy blood donors
(seronegative for HIV, HBV, andHCV) were obtained from the
Australian Red Cross Blood Service (West Melbourne, Austra-
lia). Blood from HCV-infected subjects was collected as a part
of social network study of intravenous drug users (Burnet Insti-
tute, Melbourne, Australia (51). HCV status was assessed via
serology and the presence of viral RNA at the Victorian Infec-
tious Diseases Reference Laboratory (Parkville, Australia).
Samples were HLA-typed by the Victorian Transplant and
Immunogenetics Service (West Melbourne, Australia) at the
Australian Red Cross Blood Service tissue-typing laboratory.
HLA-A*02:01-positive, HBV-negative, HIV-negative injected-
drug users were selected. Donors used in this study are listed in
Table 4. The experiments conformed to the NHMRC Code of
Practice and were approved by the University of Melbourne
Research Human Ethics Committee.
Separation of PBMCs from Whole Blood—PBMCs were sep-
arated fromperipheral blood by density gradient centrifugation
over Ficoll-Paque Plus (Sigma-Aldrich). Diluted blood was lay-
ered onto 15 ml of Ficoll-Paque Plus and centrifuged. PBMCs
were collected from the interface of the Ficoll, washed three
times, resuspended in freezing medium (10% dimethyl sulfox-
ide; Sigma-Aldrich) in heat-inactivated FCS (Bovogen Biologi-
cal, Keilor East, Australia), and stored in liquid nitrogen.
Peptides and Tetramers—The following HLA-A*02:01-re-
stricted peptides were purchased from Genscript: HCV-
NS31073–1081 and variant peptides (CINGVCWTV; CVNGVC-
WTV), influenza-NA231–239 WT and variant peptides
(CVNGSCFTV; CVNGSCFTI; CINGSCFTI; CINGTCTVV),
influenza-M158–66 (GILGFVFTL), and BMLF-1 (GLCTL-
VAML). Wild type HLA-A*02:01 and CD8-binding HLA-
A*02:01 mutant (Q115E; QE) (40) monomers were purchased
from the Immuno IDFacility (Department ofMicrobiology and
Immunology, University of Melbourne, Melbourne, Australia).
CD8 T Cell Lines—PBMCs were thawed, washed, and
rested for 1 h in RF10 (RPMI (Gibco) supplemented with
10–20%FCS, 5mMHEPES (MPBiomedicals), 100g/ml strep-
tomycin (Gibco), 100 units/ml benzylpenicillin (CSL, Parkville,
Australia), 2 mM L-glutamine (MP Biomedicals), 55 M -mer-
captoethanol (Sigma-Aldrich), and 100 mM non-essential
amino acids (Gibco)). Samples were split into stimulators and
responders at a ratio of 1:2 for healthy donors or 1:1 for HCV-
infected individuals. Stimulators were pulsed with 10 g/ml
peptide for 90 min, washed, and added to the responders.
Media half changes were done twice weekly with RF10 supple-
mented with 10–20 units/ml of IL-2 with or without 50% T cell
growth factor (supernatant fromMLA44 cell). Cultures derived
from HCV-infected individuals were supplemented with 25
units/ml IL-7 on day 3. The cultures were restimulated on day 7
and then weekly for CD8 T cell lines at a 1:10–15 stimulators
to responders ratio with C1R-HLA-A*02:01-expressing cells
pulsedwith 10g/ml peptide for 60min and gamma-irradiated
at 8,000 rad.
TABLE 5
NA231 sequences found inhuman influenzaviruses isolated from1935
to 2014
Sequences for conservation analysis were obtained from the NCBI Influenza
ResearchDatabase. Full- length sequenceswere obtained andwere aligned using the
IEDB Analysis Resource. All vaccine strains, sequences from viruses isolated within
Oceania, and all pH1N1 sequences were chosen for analysis. The frequency of each
variant is shown in the table; the underlined residues are those that vary from the
WT NA231 epitope.
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Intracellular Cytokine Staining—CD8 T cell lines were
stimulated with C1R-HLA-A*02:01-expressing cells pulsed
with 10 g/ml of peptide for 1 h at a ratio of 1:2 stimulators to
responders in the presence of IL-2. The cells were incubated for
1 h and then supplemented with 10 g/ml brefeldin A (Sigma-
Aldrich) and incubated for a further 5 h. Cells were then sur-
face-stained with CD3-PeCy7 and CD8-PerCP (BD Biosci-
ences) for 30 min and fixed in 1% paraformaldehyde (PFA;
Electron Microscopy Sciences, Hatfield, PA) for 15 min. The
cells were permeabilized with 0.3% saponin (Sigma) diluted in
PBS and stained for internal cytokines IFN (PE or FITC) and
TNF (FITC or PE) overnight (BD Biosciences). The samples
were acquired on the BD FACS Canto II (BD Biosciences) and
analyzed using Flowjo software (Treestar).
Tetramer Staining—CD8 T cell lines were stained with
tetramers for 1 h at room temperature. The cells were subse-
quently surface-stained with CD3-PeCy7, CD8-PerCP/Per-
CPCy5.5, CD27-APCH7, and CD45RA-FITC (BD Biosci-
ences) in PBS for 30 min, fixed in 1% PFA, acquired on the BD
FACS Canto II, and analyzed using Flowjo software. Themark-
ers CD27, CCR7, and CD45RA were utilized to determine the
phenotype of epitope-specific cells. Naïve cells are CD27 or
CCR7CD45RA, whereas cells of all other combinations rep-
resent memory CD8 T cells.
Magnetic Enrichment of Peptide-specific CD8 T Cells ex
Vivo—PBMCs were incubated in 20 l/1 107 cells FcR block
(Miltenyi Biotech) for 15 min after thawing. Tetramer staining
of 1 107 cells (for memory CD8 T cells) or 5 107 cells (for
naïve or low affinity CD8 T cells) was performed at a 1:100
dilution of PE- or APC-conjugated tetramers in sorter buffer
(PBS, 0.5% BSA (Gibco), 2 mM EDTA (Ajax Finechem)) for 1 h.
The cells were incubated with 100 l of PE and 100 l of
APCmicrobeads (Miltenyi Biotech) in 300 l of sorter buffer
for 30 min. The cells were thoroughly washed, positively
enriched by running twice over a LSmagnetic column (Miltenyi
Biotech), and then surface-stained with CD3-PB CD8-
PerCP Cy5.5, CD4-APCH7, and CD45RA-FITC in combi-
nation with CD27-AF700, CD14-APCH7, and CD19-
APCH7 or CCR7-APC and CD14-PeCy7 (BD Biosciences,
CA, USA) for 30 min. The samples were fixed with 1% PFA,
acquired on the BD FACS LSR II (BD Biosciences), and ana-
lyzed using Flowjo software.
FIGURE 8. PBMCs from individuals chronically infected with HCV do not expand to NA231 variant peptides in vitro. CD8
 T cell lines from donors with
chronic HCV infection were raised against WT and variant NA231 peptides, andWT or variant NS31073 peptides, or a pool of all peptides for 11–18 days (n	 2).
CD8 T cell responses toward each individual peptide were assessed in an IFNTNF ICS assay. The cells were stained (as described under “Experimental
Procedures”) and gated on lymphocytes, singlets, CD3mid-high, and CD8 T cells. a, proportion of IFNTNF production (no peptide control subtracted) by
CD8 T cells lines raised against NA231-WT (CVNGSCFTV) (panel i), NA231-I9 CVNGSCFTI (panel ii), NA231-I2-I9 (CINGSCFTI) (panel iii), and NA231-I2-T5-T7-V8
(CINGTCTVV) (panel iv) in response to each peptide. b, proportion of IFNTNF production toward each peptide (no peptide control subtracted) by CD8
T cells lines raised againstWTNS31073 (CINGVGWTV) andNS31073-V2 (CVNGVGWTV). c, proportion of IFN
TNF production (no peptide control subtracted)
by CD8 T cells raised against pooled peptides, in response to each peptide.
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Single-cell Sorting and Multiplex PCR—Epitope-specific
CD8 T cells were antibody-stained, and CD3CD8-
tetramer cells were single-cell sorted directly into 96-well
PCR plates (Eppendorf, Hamburg, Germany) using the BD
FACS Aria II (BD Biosciences). cDNA was synthesized using
the VILO RT kit (Invitrogen). Multiplex nested PCR was per-
formed as previously described (34, 52). Briefly, the external
round was performed with 40 V-external and 27 V-external
primers and the C-external and C external primers. The
internal PCR rounds were performed individually with the 40
V-internal and C-internal or the 27 V-internal and the
C-internal primers (34, 52). PCR products were detected on a
2% agarose gel and purified using Exosap (Affymetrix) or Exo-
star (GE Healthcare). The sequencing reaction was performed
using the C-internal primer and BigDyeV3.1 (Applied Biosys-
tems) and cleaned on DyeEx sequencing plates (Qiagen).
Sequencing was performed by the Pathology Department at
the University of Melbourne (Melbourne, Australia). The
sequences were analyzed using FinchTV, and V and J region
usage was identified by IMGT query (53). CDR3 amino acid
sequences described within the manuscript are productive
(without stop codons and with an in-frame junction) TCR
pairs and start from CDR3 position 1, as determined by the
IMGT software. CDR3 length and motifs are from position 4.
Samples with two  or  chains were dissected by performing
an internal round of PCR with the specific individual primers
and then sequenced as above.Where possible, both chainswere
resolved; however, in a few instances only the dominant chain
could be resolved. Samples with TRBV19 (M158CD8 T cell
repertoire) had the internal round of PCR repeated with
TRBV19 andwere subsequently sequencedwith the TRBV19 for-
ward primer. IMGT nomenclature was used (54). CDR3 motif
conservation analysis (Fig. 8) was generated using the Seq2Logo
2.0 server (55)using theShannon logo type, noclustering, 0weight
on prior, and seq2logo default amino acid color settings.
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